Interpretation of modified prescription for pharmacoeconomic analysis of New Zealand.
- Author:
Xin WANG
1
;
Xia SU
;
Yan GAO
;
Yanming XIE
;
Yongyan WANG
Author Information
1. Beijing Bionovo Medicine Development Co., Ltd., Beijing 100024, China. wangxin@bionovo.com.cn
- Publication Type:Journal Article
- MeSH:
Costs and Cost Analysis;
Economics, Pharmaceutical;
Humans;
New Zealand
- From:
China Journal of Chinese Materia Medica
2011;36(20):2840-2843
- CountryChina
- Language:Chinese
-
Abstract:
The Prescription for Pharmacoeconomic Analysis (PFPA) of New Zealand was firstly published in 1999. The original version was reviewed in 2004 and version 2, approved and published in 2007, is the living document. The main purpose for this guideline is to provide an overview of the methods PHARMAC (Pharmaceutical Management of Agency) uses when conducting cost-utility analysis. Compared with version 1, version 2 involved and discussed the most frequently mentioned issues in pharmacoeconomic guidelines around the world. This paper describes the distinguishes between version 1 and 2, the advantages of version 2 as well as the amendments that will be made in PHARMAC's future work, in order to provide meaningful advice for standardizing and documenting methods in China
